Protalix BioTherapeutics (PLX) Payables (2016 - 2025)
Historic Payables for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $5.4 million.
- Protalix BioTherapeutics' Payables fell 7254.43% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year decrease of 7254.43%. This contributed to the annual value of $4.5 million for FY2024, which is 493.06% up from last year.
- Per Protalix BioTherapeutics' latest filing, its Payables stood at $5.4 million for Q3 2025, which was down 7254.43% from $6.7 million recorded in Q2 2025.
- In the past 5 years, Protalix BioTherapeutics' Payables ranged from a high of $19.6 million in Q3 2024 and a low of $4.1 million during Q1 2025
- Its 5-year average for Payables is $13.0 million, with a median of $14.4 million in 2022.
- As far as peak fluctuations go, Protalix BioTherapeutics' Payables skyrocketed by 4645.03% in 2023, and later tumbled by 7804.48% in 2025.
- Quarter analysis of 5 years shows Protalix BioTherapeutics' Payables stood at $16.4 million in 2021, then fell by 25.33% to $12.3 million in 2022, then plummeted by 64.8% to $4.3 million in 2023, then grew by 4.93% to $4.5 million in 2024, then grew by 18.57% to $5.4 million in 2025.
- Its Payables stands at $5.4 million for Q3 2025, versus $6.7 million for Q2 2025 and $4.1 million for Q1 2025.